636 related articles for article (PubMed ID: 29532589)
1. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
Wang B; Carey I; Bruce M; Montague S; Dusheiko G; Agarwal K
J Viral Hepat; 2018 Aug; 25(8):886-893. PubMed ID: 29532589
[TBL] [Abstract][Full Text] [Related]
2. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
[TBL] [Abstract][Full Text] [Related]
3. Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients.
Martinot-Peignoux M; Lapalus M; Maylin S; Boyer N; Castelnau C; Giuily N; Pouteau M; Moucari R; Asselah T; Marcellin P
J Viral Hepat; 2016 Nov; 23(11):905-911. PubMed ID: 27375231
[TBL] [Abstract][Full Text] [Related]
4. Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy.
Cheung KS; Seto WK; Wong DK; Lai CL; Yuen MF
J Viral Hepat; 2017 Aug; 24(8):654-661. PubMed ID: 28185363
[TBL] [Abstract][Full Text] [Related]
5. Baseline and on-treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals.
Hwang SY; Yoo SH; Chang HY; Kim S; Lee JI; Lee KS; Cho YY; Joon KH; Lee HW
J Viral Hepat; 2023 Jan; 30(1):39-45. PubMed ID: 36321949
[TBL] [Abstract][Full Text] [Related]
6. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
7. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B.
Chuaypen N; Posuwan N; Payungporn S; Tanaka Y; Shinkai N; Poovorawan Y; Tangkijvanich P
Liver Int; 2016 Jun; 36(6):827-36. PubMed ID: 26678018
[TBL] [Abstract][Full Text] [Related]
8. Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy.
Hsu WF; Chen CF; Lai HC; Su WP; Lin CH; Chuang PH; Chen SH; Chen CH; Wang HW; Huang GT; Peng CY
Liver Int; 2018 Apr; 38(4):627-635. PubMed ID: 28857411
[TBL] [Abstract][Full Text] [Related]
9. Relationship between hepatitis B core-related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues.
Sonneveld MJ; van Oord GW; van Campenhout MJ; De Man RA; Janssen HLA; de Knegt RJ; Boonstra A; van der Eijk AA
J Viral Hepat; 2019 Jul; 26(7):828-834. PubMed ID: 30896057
[TBL] [Abstract][Full Text] [Related]
10. Predictors for efficacy of combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B.
Li H; Wang H; Peng C; Zheng X; Liu J; Weng ZH; Yang DL
J Huazhong Univ Sci Technolog Med Sci; 2017 Aug; 37(4):547-555. PubMed ID: 28786051
[TBL] [Abstract][Full Text] [Related]
11. Performance of Hepatitis B Core-Related Antigen Versus Hepatitis B Surface Antigen and Hepatitis B Virus DNA in Predicting HBeAg-positive and HBeAg-negative Chronic Hepatitis.
Zhang ZQ; Wang YB; Lu W; Liu DP; Shi BS; Zhang XN; Huang D; Li XF; Zhou XL; Ding RR
Ann Lab Med; 2019 Jan; 39(1):67-75. PubMed ID: 30215232
[TBL] [Abstract][Full Text] [Related]
12. Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients.
Wang L; Cao X; Wang Z; Gao Y; Deng J; Liu X; Zhuang H
J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355757
[TBL] [Abstract][Full Text] [Related]
13. Performance of serum HBcrAg in chronic hepatitis B patients with 8-year nucleos(t)ide analogs therapy.
Wang ML; Deng R; Chen EQ; Tao CM; Liao J; Zhou TY; Wang J; Tang H
Clin Res Hepatol Gastroenterol; 2019 Jun; 43(3):301-309. PubMed ID: 30497844
[TBL] [Abstract][Full Text] [Related]
14. Early Serum HBsAg Drop Is a Strong Predictor of HBeAg Seroconversion and HBsAg Loss to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients with Prior Nucleos(t)ide Analogue Exposure.
Chen Q; Zhang J; Huang J; Quan B; Wu X; Deng S; Han W
Med Sci Monit; 2019 Jun; 25():4665-4674. PubMed ID: 31230063
[TBL] [Abstract][Full Text] [Related]
15. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment.
Wang X; Chi X; Wu R; Xu H; Gao X; Yu L; Liu L; Zhang M; Tan Y; Niu J; Jin Q
Virol J; 2021 Jan; 18(1):4. PubMed ID: 33407619
[TBL] [Abstract][Full Text] [Related]
16. Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy.
Carey I; Gersch J; Wang B; Moigboi C; Kuhns M; Cloherty G; Dusheiko G; Agarwal K
Hepatology; 2020 Jul; 72(1):42-57. PubMed ID: 31701544
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
[TBL] [Abstract][Full Text] [Related]
18. Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues.
Wang Y; Liao H; Deng Z; Liu Y; Bian D; Ren Y; Yu G; Jiang Y; Bai L; Liu S; Liu M; Zhou L; Chen Y; Duan Z; Lu F; Zheng S
J Viral Hepat; 2022 Jun; 29(6):420-431. PubMed ID: 35274400
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy.
Liao H; Liu Y; Li X; Wang J; Chen X; Zou J; Li Q; Liu L; Wang J; Huang B; Lu F; Xu D
Antivir Ther; 2019; 24(2):105-115. PubMed ID: 30511941
[TBL] [Abstract][Full Text] [Related]
20. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
